prof.dr. M.J. IJzerman (Maarten)

Scientific visitors

About Me

Maarten J. IJzerman is professor and head of Cancer Health Services Research in the University of Melbourne and Peter MacCallum Cancer Centre and a part-time professor in the University of Twente's TechMed Centre. His international work is focussed on the health economics and health services implications of personalised medicine, including drug treatment sequencing and the use of complex genomic sequencing. He develops and applies new methods for value assessment of medical technologies, in particular molecular diagnostics for precision oncology. He is a pioneer in the field of early Health Technology Assessment, supporting the clinical translation of medical innovation by modelling their health and economic impact in an early stage of development. 

Before moving to Melbourne in 2018, he was the founding chair of the Department of Health Technology and Services Research (2007-2015), director of education for Health Sciences program (2007-2011), acting director of the MIRA institute for Biomedical Engineering and Technical Medicine (2013-2014) and vice-dean for Health & Biomedical Technology in the Faculty of Science and Technology (2015-2017). Before then, he worked as a visiting scholar in different academic centres in the USA and Canada and was the scientific director of Roessingh Research and Development (2000-2007). 

Maarten has supervised many MSc and PhD students in several UT degree programs (TM, HS, BME and IEM) and is a mentor to early-to-mid career academics globally. 


Social Sciences
Health Economics
Medicine & Life Sciences
Cost-Benefit Analysis
Costs And Cost Analysis
Decision Support Techniques
Delivery Of Health Care

Ancillary Activities

  • University of Melbourne / VCCC
    Director Cancer Health Services Research
  • Bestuur Stichting International Health Technology Services
  • NMS Ventures b.v.
    Advieswerkzaamheden consultancy


Enzing, J. J., Knies, S., Engel, J. , IJzerman, M. J., Sander, B., Vreman, R., Boer, B., & Brouwer, W. B. F. (2022). Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports. Cost effectiveness and resource allocation, 20(1), [46]. https://doi.org/10.1186/s12962-022-00383-y
Grazziotin, L. R., Currie, G., Twilt, M. , IJzerman, M. J. , Kip, M. M. A. , Koffijberg, H., Bonsel, G., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R. S. M., Armbrust, W., van den Berg, J. M., & Marshall, D. A. (2022). Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis. Pediatric Rheumatology, 20(1), 1-12. [51]. https://doi.org/10.1186/s12969-022-00713-7
Kip, M. M. A., de Roock, S., Currie, G., Marshall, D. A., Grazziotin, L. R., Twilt, M., Yeung, R. S. M., Benseler, S. M., Vastert, S. J., Wulffraat, N. M., Swart, J. F. , & IJzerman, M. J. (2022). Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: A real-world data analysis. Rheumatology, 1-11. https://doi.org/10.1093/rheumatology/keac299
Grazziotin, L. R., Currie, G., Twilt, M. , Ijzerman, M. J. , Kip, M. M. A. , Koffijberg, H., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R. S. M., & Marshall, D. A. (2022). Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 20(1), [25]. https://doi.org/10.1186/s12969-022-00682-x
Currie, G. R., Pham, T., Twilt, M. , IJzerman, M. J., Hull, P. M. , Kip, M. M. A., Benseler, S. M., Hazlewood, G. S., Yeung, R. S. M., Wulffraat, N. M., Swart, J. F., Vastert, S. J., & Marshall, D. A. (2022). Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient, 15(5), 599-609. https://doi.org/10.1007/s40271-022-00575-x
Vu, M. , Degeling, K., Thompson, E. R., Blombery, P., Westerman, D. , & IJzerman, M. J. (2022). Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology, 108(6), 469-485. https://doi.org/10.1111/ejh.13755

UT Research Information System

Google Scholar Link


I am committed to teaching in graduate programs in the University of Twente and Melbourne as well as international short-courses for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Affiliated Study Programmes


Courses Academic Year  2022/2023

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

Courses Academic Year  2021/2022

News on utwente.nl

  • https://www.utoday.nl/covid-19-research-at-ut/68467/delays-in-cancer-treatments-due-to-corona-crisis
  • https://www.utwente.nl/en/news/2018/3/39094/maarten-ijzerman-to-lead-world-class-cancer-research-program-in-melbourne



Contact Details

Visiting Address

University of Twente
Drienerlolaan 5
7522 NB Enschede
The Netherlands

Navigate to location

Mailing Address

University of Twente
P.O. Box 217
7500 AE Enschede
The Netherlands

Social Media